MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'cladribine'. Sat, 03 Sep 2011 03:02:05 +0100 http://www.medworm.com/index.php?rid=4382876&cid=t_288692_129_f&fid=36038&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Ftrevis-life-with-multiple-sclerosis-ms%2Fa-big-news-day-for-multiple-sclerosis-drugs-and-stock-markets%2F I suppose that it says a lot about our disease (as well as our society) when the vast amount of reporting on multiple sclerosis drug therapy is done in the financial papers and investment pages… The 24/7 news cycle is no longer just reserved for word of wars, terrorist attacks, and what celeb did what with whom in the wee hours on a Pacific atoll. Most of North America woke to — or in the case of a couple pharmaceutical CEOs, were awakened by — news that the European cousin to our Food and Drug Administration’s (FDA) drug approval wing, the Committee for Medicinal Products for Human Use (CHMP) had laid waste to two balance sheets while cementing another as the owner of the only MS pill OK’d for use in the Euro zone. For drug giant Merck, it’s been a rough autumn which has b... Life with MS blogs http://www.medworm.com/rss/comments.php?id=4382876 Fri, 21 Jan 2011 23:05:01 +0100 4382876 http://www.medworm.com/index.php?rid=4098231&cid=t_288692_129_f&fid=36038&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Ftrevis-life-with-multiple-sclerosis-ms%2Fms-newsmakers-series-tysabri-6-years-on%2F As one new oral therapy drug for MS makes its way to the world market and another, Cladribine Novaplus (Cladribine), stumbles in approval proceedings, many of our readers still have questions about Tysabri (Natalizumab). This summer, we asked what questions you would like to ask the experts about this method of treatment which many tout as their lifeline but strikes fear into others. These MS Newsmaker series articles have taken far longer to execute than I (or my patient editorial director, Rose) ever thought they would! Our latest in the series, MS and Tysabri 2010, has just been posted and we’re very excited about the information therein! Your questions led you an in-depth discussion with leaders from around the world. We spoke to the drug’s manufacturer, to federal regulators, and ... Life with MS blogs http://www.medworm.com/rss/comments.php?id=4098231 Fri, 22 Oct 2010 21:17:39 +0100 4098231 http://www.medworm.com/index.php?rid=3193804&cid=t_288692_111_f&fid=36048&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FkN49ebUApno%2F News that there is progress in developing oral drugs for multiple sclerosis, a neurological disease that strips the ability of the nerves to send impulses from the brain, is raising hope so millions of patients with the disease. The biggest plus of medications like Cladribine (Merck) and Fingolimod (Novartis) is that they are taken by mouth. Right now, the only medications that could slow down the progress of MS are taken by injection. Cladribine would only be taken for a few days each year, while fingolimod is taken every day. However, researchers are cautioning people about the serious side effects that may come with the drugs. It turns out that both medications lower the immune system’s defenses, making patients much more vulnerable to infection. According to news reports, two peo... A Hearty Life blogs http://www.medworm.com/rss/comments.php?id=3193804 Thu, 21 Jan 2010 16:11:20 +0100 3193804 http://www.medworm.com/index.php?rid=2789086&cid=t_288692_122_f&fid=34755&url=http%3A%2F%2Fneuropsychological.blogspot.com%2F2009%2F09%2Fmercks-cladribine-and-multiple.html From FierceBiotech:Merck KGaA pulls ahead in hot oral MS drug raceBy John CarrollSeptember 11, 2009 — 8:22am ETResearchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential as a new therapy for multiple sclerosis. Patients taking a short course of the therapy were more likely to go two years without seeing the disease flare up, and that could prove crucial for the developer as it prepares to make its case that cladribine should be neurologists' preferred choice among a slate of experimental oral MS therapies.Read the full article (Source: BrainBlog) BrainBlog blogs http://www.medworm.com/rss/comments.php?id=2789086 Fri, 11 Sep 2009 21:34:00 +0100 2789086